Cargando…

Targeting RET-rearranged non-small-cell lung cancer: future prospects

Non-small-cell lung cancer (NSCLC) patients with mutated or rearranged oncogene drivers can be treated with upfront selective inhibitors achieving higher response rates and longer survival than chemotherapy. The RET gene can undergo chromosomal rearrangements in 1%–2% of all NSCLC patients, involvin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bronte, Giuseppe, Ulivi, Paola, Verlicchi, Alberto, Cravero, Paola, Delmonte, Angelo, Crinò, Lucio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433115/ https://www.ncbi.nlm.nih.gov/pubmed/30962732 http://dx.doi.org/10.2147/LCTT.S192830

Ejemplares similares

Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer
por: Andrikou, Kalliopi, et al.
Publicado: (2023)

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer
por: De Matteis, Serena, et al.
Publicado: (2019)

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer
por: Verlicchi, Alberto, et al.
Publicado: (2023)

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
por: Ulivi, Paola, et al.
Publicado: (2021)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
por: Ulivi, Paola, et al.
Publicado: (2022)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Unveiling mutational dynamics in non‐small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA
por: Pasini, Luigi, et al.
Publicado: (2021)

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
por: Nicolini, Fabio, et al.
Publicado: (2020)

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
por: Danesi, Valentina, et al.
Publicado: (2022)

Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
por: Ackermann, Christoph Jakob, et al.
Publicado: (2019)

Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
por: Nicolini, Fabio, et al.
Publicado: (2020)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

Current management of RET rearranged non-small cell lung cancer
por: Stinchcombe, Thomas E
Publicado: (2020)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
por: Gianni, Caterina, et al.
Publicado: (2021)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

Therapeutic strategies in RET gene rearranged non-small cell lung cancer
por: Drusbosky, Leylah M., et al.
Publicado: (2021)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
por: Takeuchi, Shinji, et al.
Publicado: (2021)

RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer
por: Sasaki, Hidefumi, et al.
Publicado: (2012)

RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
por: Tsuta, K, et al.
Publicado: (2014)

1p/19q codeletion and RET rearrangements in small-cell lung cancer
por: Lu, Hongyang, et al.
Publicado: (2016)

Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements
por: Digumarthy, Subba R., et al.
Publicado: (2020)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Zhang, Quxia, et al.
Publicado: (2018)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022)

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2020)

Decade in review: a new era for RET-rearranged lung cancers
por: Choudhury, Noura J., et al.
Publicado: (2020)

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China
por: Li, Tao, et al.
Publicado: (2023)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients
por: Feng, Junnan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oh2glisnc201pgpoe0mtuktbsk